

Supplementary Materials




Figure S1. Specificity test of ASFV-positive and -negative sera with purified recombinant p30 (0.4 µg /lane). Western blot of the field samples used as serum panel: **(A), (B), (C), (D)** Purified p30 were diluted to 0.4 µg per lane (lane 1–40 and lane N1–N7) in gel electrophoresis, and tested separately with 1000-fold diluted 40 ASFV-positive sera against ASFV. Then, 98 ASFV-negative sera were divided into 7 fractions (N1, N2, N3, N4, N5, N6, N7), and 14 sera in each fraction were tested together with the p30 protein. There were 1 to 40-40 ASFV-positive serum samples, and N1 to N7-7 fractions with 14 ASFV-negative serum samples in each fraction. **(E)** SDS-PAGE analysis of p30 protein. M1—protein ladder purchased from Genedirex, M2—protein ladder purchased from Thermo Fisher, 41—purified p30 (0.4 µg). Ten sera used in bELISA were selected from the aforementioned serum panel. Therein, five positive sera against ASFV corresponded to lane 1 to lane 5, and five ASFV-negative sera corresponded to first 5 numbered sera in fraction N1. Then, 40 positive ASFV sera and 98 negative ASFV sera were verified truly by Western blot.

